ESR1 and breast carcinoma: Additionally, Wang and his colleagues 2019 demonstrated the DC50 levels of ERD‐308, in MCF7 and T47D ER+ breast cancer cell lines, an extremely powerful and efficient ER degrader, respectively (Zhou et al. 2018).